This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08989/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08989/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB08989/identifier/wikipedia/

Statements

Subject Item
n2:DB08989
rdf:type
n3:Drug
n3:description
Etamivan (INN) or ethamivan (USAN), trade name Analepticon, is a respiratory stimulant drug related to nikethamide. It is no longer used in the United States.
n3:group
withdrawn
owl:sameAs
n6:DB08989
dcterms:title
Etamivan
adms:identifier
n9:D04080 n10:Etamivan n11:DB08989
n3:synonym
Ethamivan
n3:synthesisReference
U.S. Patent 2,641,612.
n3:IUPAC-Name
n4:271B6292-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6298-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6297-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6294-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6295-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6296-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6290-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6291-363D-11E5-9242-09173F13E4C5 n4:271B628E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B628F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B629E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B629F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6299-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B629A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B629C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B629B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B629D-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
304-84-7
n3:Bioavailability
n4:271B62A4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62A6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62A7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B62A8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62A3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62A2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62A5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6293-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B62A0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62A1-363D-11E5-9242-09173F13E4C5